Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first‐line setting

BACKGROUND: Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) are recommended as first‐line treatment in non‐small cell lung cancer (NSCLC) patients with sensitizing EGFR mutations. The sequential use of different EGFR‐TKIs has been reported to demonstrate improvement in overal...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwok, Wang Chun, Ho, James Chung Man, Tam, Terence Chi Chun, Ip, Mary Sau Man, Lam, David Chi Leung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284183/
https://www.ncbi.nlm.nih.gov/pubmed/35668712
http://dx.doi.org/10.1111/1759-7714.14528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284183/
https://www.ncbi.nlm.nih.gov/pubmed/35668712
http://dx.doi.org/10.1111/1759-7714.14528

Ejemplares similares